Clinical Trials /

Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)

NCT04790708

Description:

The rationale behind the purpose of this study lays on: - the evidence that PRRT could represent a valuable treatment for the majority of patients with neuroendocrine tumor (NET) in disease progression, operated or inoperable, presenting lesions expressing somatostatin receptors and for which standard treatments are not already available; - the current impossibility of acquiring on the market radiolabelled analogues of somatostatin used for PRRT with marketing authorisation; - the need to collect a larger case history than in previous studies; - the need to stratify the various histotypes based on the response obtained; - the need to define new treatment schemes that guarantee the maximum efficacy and the lowest possible toxicity - with low cumulative (and per cycle) activities radiopharmaceutical and according to the concept of dose hyperfractionation - with a view to an optimal balance between risk and benefit.

Related Conditions:
  • Neuroendocrine Tumor
Recruiting Status:

Recruiting

Phase:

N/A

Trial Eligibility

Document

Title

  • Brief Title: Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)
  • Official Title: Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors

Clinical Trial IDs

  • ORG STUDY ID: 160990
  • SECONDARY ID: 2016-005129-35
  • NCT ID: NCT04790708

Conditions

  • Neuroendocrine Tumors
  • Peptide Receptor Radionuclide Therapy (PRRT)

Purpose

The rationale behind the purpose of this study lays on: - the evidence that PRRT could represent a valuable treatment for the majority of patients with neuroendocrine tumor (NET) in disease progression, operated or inoperable, presenting lesions expressing somatostatin receptors and for which standard treatments are not already available; - the current impossibility of acquiring on the market radiolabelled analogues of somatostatin used for PRRT with marketing authorisation; - the need to collect a larger case history than in previous studies; - the need to stratify the various histotypes based on the response obtained; - the need to define new treatment schemes that guarantee the maximum efficacy and the lowest possible toxicity - with low cumulative (and per cycle) activities radiopharmaceutical and according to the concept of dose hyperfractionation - with a view to an optimal balance between risk and benefit.

Trial Arms

NameTypeDescriptionInterventions
Midgut NETsExperimental75 patients affected by non-functional and functional NETs arising from: stomach, duodenum, jejunum, ileum, colon and rectum.
    Pancreatic NETsExperimental75 patients affected by non-functional and functional NETs arising from Pancreas.
      Bronchial NETsExperimental25 patients affected by non-functional and functional Bronchial NETs.
        Sympathetic-Adrenergic axis NEtsExperimental25 patients affected by non-functional and functional: Pheochromocytoma, Paraganglioma and Neuroblastoma
          Other NetsExperimental25 patients affected by non-functional and functional NETs arising from Skin, Thyroid (medullary thyroid and anaplastic cancer) and Parathyroids.
            Cancers of Unknown Primary Origin (CUP) NETsExperimental25 patients affected by non-functional and functional unknown primary NETs

              Eligibility Criteria

                      Inclusion Criteria:
              
                        -  1. Age ≥18 years, of both sexes, of any ethnicity;
              
                        -  2. Cyto-histological and immunohistochemical diagnosis of NET;
              
                        -  3. Evaluation of the cell proliferation index by studying Ki-67 and / or E3
                           ubiquitin-protein ligase (MIB-1).
              
                        -  4. Illness measurable according to RECIST 1.1 criteria by imaging conventional (CT
                           with contrast medium or MRI with contrast medium) not earlier than two months with
                           respect to enrollment;
              
                        -  5. Elevated expression of somatostatin receptors documented by PET-CT with
                           68Ga-DOTATOC in the target lesion (s). It is defined as "high expression of
                           somatostatin receptors "a ratio of Maximum standardized uptake value (SUVmax) lesion /
                           Mean standardized uptake value (SUVmean) muscle ≥ 4: 1 calculated with
                           semi-quantitative analysis on examination PET-CT with 68Ga-DOTATOC;
              
                        -  6. Dosage of Chromogranin A (and any other specific markers) not prior to two months
                           of enrollment;
              
                        -  7. Evaluation of glucose metabolism in the target lesion (s) by PET-CT with 18F-FDG;
              
                        -  8. Preserved haematological, hepatic and renal parameters, in particular: white blood
                           cells ≥2500 / μL; platelets ≥ 90000 / μL; hemoglobin ≥ 9 gr / dL; creatinine ≤ 2 mg /
                           dL; bilirubin ≤ 2.5 mg / dL
              
                        -  9. Eastern Cooperative Oncology Group (ECOG) performance status ≤2;
              
                        -  10. Life expectancy ≥ 6 months;
              
                        -  11. Stable or progressive disease, at any stage, both in operated patients that
                           inoperable;
              
                        -  12. Absence of standard treatments already documented and of equal effectiveness;
              
                        -  13. Absence of surgical, chemotherapy and / or radiotherapy treatments for at least 30
                           days. On the other hand, patients in therapy with somatostatin analogues or biologics,
                           such as mechanistic target of rapamycin (m-TOR) inhibitors;
              
                        -  14. Voluntary participation in the study by signing the consent form informed, after
                           reading and complete understanding of the information notes.
              
                      Exclusion Criteria:
              
                        -  1. Lack of the requirements listed above;
              
                        -  2. State of pregnancy;
              
                        -  3. Breastfeeding and relative refusal to suspend breastfeeding;
              
                        -  4. Participation in another therapeutic experimental clinical protocol in the four
                           weeks prior to the PRRT;
              
                        -  5. Bone marrow invasion of disease> 25% confirmed;
              
                        -  6. Previous extensive radiotherapy treatments.
                    
              Maximum Eligible Age:N/A
              Minimum Eligible Age:18 Years
              Eligible Gender:All
              Healthy Volunteers:No

              Primary Outcome Measures

              Measure:Disease Control Rate
              Time Frame:12 months
              Safety Issue:
              Description:Post-treatment evaluation will be performed with: a clinical examination; a comparative morphological re-evaluation, using version 1.1 of Response evaluation criteria in solid tumors (RECIST criteria) on Computed Tomography (CT); a comparative functional re-evaluation, performed both on 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission computed tomography (PET/CT) and Gallium-68 (68Ga)-DOTATOC PET/CT using visual and semi-quantitative parameters (such as SUVmax). Based on all these parameters, Disease Control Rate will be labelled as: Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progression Disease (PD).

              Secondary Outcome Measures

              Measure:Progression Free Survival
              Time Frame:6 months
              Safety Issue:
              Description:Progression free survival is defined as the time intercurrent from treatment start to the date of first observation of documented disease progression or death due to any cause.
              Measure:Overall Survival
              Time Frame:6 months
              Safety Issue:
              Description:Overall survival is defined as the time intercurrent from treatment start to the date of death due to any cause, or the date of last contact.
              Measure:Evaluation of PRRT Safety
              Time Frame:6 months
              Safety Issue:
              Description:The evaluation of Treatment-Emergent Adverse Events, defined as any G3/G4 toxicity. The evaluation will be performed during every treatment cycle and after 12, 18, 24, 30, 36 and 42 months after the last treatment cycle and will be based on version 4.0 of Common Terminology Criteria for Adverse Events (CTC-AE) toxicity criteria.
              Measure:Evaluation of Quality of Life
              Time Frame:6 months
              Safety Issue:
              Description:Quality of Life (QoL) will be evaluated with quality of life questionnaire, version 3 (QLQ-C30) by European Organisation for Research and Treatment of Cancer (EORTC). The questionnaire includes five functional scales, three symptom scales, a global health status / QoL scale, and six single items. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

              Details

              Phase:N/A
              Primary Purpose:Interventional
              Overall Status:Recruiting
              Lead Sponsor:University Hospital of Ferrara

              Trial Keywords

              • Neuroendocrine Tumors
              • 90Y
              • 177Lu
              • PRRT

              Last Updated

              March 10, 2021